What are the indications, dosing regimen, contraindications, precautions, and common side effects of Emgality (galcanezumab) for adult patients with migraine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Emgality (Galcanezumab) for Migraine Prevention

Emgality is FDA-approved for preventive treatment of migraine in adults and for episodic cluster headache, administered as a 240 mg loading dose (two 120 mg subcutaneous injections) followed by 120 mg monthly for migraine prevention. 1

Indications

Emgality is indicated for:

  • Preventive treatment of migraine in adults (episodic or chronic)
  • Treatment of episodic cluster headache in adults 1

The 2025 American College of Physicians guideline includes galcanezumab among CGRP monoclonal antibodies as a conditional recommendation for episodic migraine prevention in nonpregnant adults, though notes low-certainty evidence 2. Real-world data from the TRIUMPH study demonstrates superior effectiveness compared to traditional oral preventives, with 46.6% of galcanezumab patients achieving clinically meaningful response versus 34.5% with traditional oral medications at 3 months 3.

Dosing Regimen

For Migraine Prevention:

  • Loading dose: 240 mg (two consecutive 120 mg subcutaneous injections) once
  • Maintenance: 120 mg subcutaneously once monthly
  • If dose missed: administer as soon as possible, then resume monthly schedule from that date 1

For Episodic Cluster Headache:

  • 300 mg (three consecutive 100 mg subcutaneous injections) at cluster period onset
  • Continue monthly until end of cluster period 1

Administration Details:

  • Subcutaneous injection only
  • Injection sites: abdomen, thigh, back of upper arm, or buttocks
  • Rotate sites; avoid tender, bruised, red, or hard areas
  • Allow to reach room temperature for 30 minutes before injection (do not use heat source)
  • Do not shake
  • Inspect for particles/discoloration; discard if cloudy or contains particles
  • Available as single-dose prefilled pen (120 mg/mL) or prefilled syringe (120 mg/mL or 100 mg/mL) 1

Contraindications

Serious hypersensitivity to galcanezumab-gnlm or any excipients 1

This is the only absolute contraindication listed in the FDA label.

Warnings and Precautions

Hypersensitivity Reactions (Most Critical):

  • Can include dyspnea, urticaria, rash, anaphylaxis, and angioedema
  • May occur days after administration and be prolonged
  • If serious/severe reaction occurs: discontinue immediately and initiate appropriate therapy 1

Hypertension:

  • New-onset or worsening of pre-existing hypertension may occur
  • Monitor blood pressure, particularly in patients with cardiovascular risk factors 1

Raynaud's Phenomenon:

  • New-onset or worsening of pre-existing Raynaud's phenomenon reported
  • Counsel patients on recognition of symptoms 1

Common Adverse Effects

Injection site reactions are the most common adverse effect (≥2% and at least 2% greater than placebo) 1

Additional adverse events from clinical trials and real-world data:

  • Injection site pain
  • Nasopharyngitis
  • Upper respiratory tract infection
  • Constipation (most common in real-world studies) 4

The overall adverse event rate in real-world studies was 25% at 6 months and 35% at 12 months, with most events being mild 4. Importantly, the rate of anti-drug antibody development did not differ significantly from placebo 5.

Clinical Effectiveness

Galcanezumab demonstrates rapid onset of action, with significant reduction in migraine headache days evident within the first month of treatment 6. The effect is maintained throughout treatment duration and gradually diminishes without rebound headache upon cessation 6.

In head-to-head real-world comparisons, galcanezumab showed superior effectiveness versus:

  • Topiramate: 48.8% vs 37.2% responder rate at 3 months
  • Amitriptyline: 49.7% vs 23.3% responder rate at 3 months 7

Over 60% of patients achieve ≥50% reduction in monthly migraine/headache days within 3 months, with effects increasing gradually up to 12 months 4.

Key Clinical Pearls

  • Onset of action is rapid: Lower percentage of patients experience migraine on the first day after injection compared to placebo 6
  • No medication overuse rebound: Gradual loss of effect upon discontinuation without rebound headache 6
  • Convenient dosing: Monthly administration improves adherence compared to daily oral preventives
  • Hypersensitivity monitoring: Educate patients that reactions can be delayed by days and prolonged 1
  • Patient selection: Particularly effective in patients who have failed multiple traditional oral preventives 8

References

Related Questions

What is the appropriate dosing regimen for Emgality (galcanezumab) for migraine prophylaxis in adults?
What are the recommended dosing guidelines for Emgality (galcanezumab) in adults with migraine and episodic cluster headache, including loading and maintenance doses and contraindications?
What preventive treatment is recommended for a 46-year-old woman with chronic migraines occurring twice weekly who has not responded to triptans (e.g., consider galcanezumab [Emgality])?
Can Emgality (galcanezumab) and Aimovig (erenumab) be used concurrently for migraine prevention?
Can calcitonin gene-related peptide (CGRP) inhibitors, such as galcanezumab (galcanezumab) or erenumab (erenumab), be used to treat patients with abdominal migraine or gastroparesis, particularly those with a history of migraines?
Does a positive FADIR (flexion‑adduction‑internal rotation) test indicate that surgical therapy would be preferred?
For a 65-year-old woman with an upper gastrointestinal bleed and a prosthetic heart valve, should prophylactic cefazolin be administered 30 minutes before the endoscopic procedure?
What is the ICD‑10‑CM diagnosis code for trospium (used to treat overactive bladder) and the ICD‑10‑PCS code for its oral administration?
What is the protocol for managing persistent high fever that does not respond to intravenous paracetamol in a patient with suspected or confirmed viral dengue infection?
In a 62-year-old patient with prediabetes, hypertension, total cholesterol 155 mg/dL, LDL 88 mg/dL, HDL 32 mg/dL, and triglycerides 300 mg/dL, is initiating fenofibrate appropriate?
Can bupropion (Wellbutrin) be used safely in patients with a history of tardive dyskinesia, and what dosing and monitoring are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.